

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Nivolumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6310]

Final Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 Company Bristol-Myers Squibb (nivolumab) Patient/carer groups Asthma and Lung UK Black Health Agency for Equality Cancer Black Care Helen Rollason Cancer Charity Independent Cancer Patients Voice Macmillan Cancer Support Maggie's Centres Marie Curie Oncogene-Driven Lung Cancer Patient Alliance UK Roy Castle Lung Cancer Foundation South Asian Health Foundation Specialised Healthcare Alliance Tenovus Cancer Care UK Lung Cancer Coalition 	 General All Wales Therapeutics and Toxicology Centre Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health – Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Confederation Scottish Medicines Consortium Welsh Government Welsh Health Specialised Services Committee
 Healthcare professional groups Association of Anaesthetists Association of Cancer Physicians Association of Respiratory Nurse Specialists Association of Surgeons of Great Britain and Ireland British Geriatrics Society British Institute of Radiology British Oncology Pharmacy Association British Psychosocial Oncology Society British Society of Interventional Radiology British Thoracic Oncology Group British Thoracic Society 	 Comparator companies Aspire Pharma (pemetrexed) AstraZeneca (durvalumab) Bristol Myers Squibb (paclitaxel) Dr Reddy's Laboratories (pemetrexed) Eli Lilly (pemetrexed) Genus Pharmaceuticals (pemetrexed) Medac (oxaliplatin) Merck Sharp & Dohme UK (pembrolizumab) Pfizer (cisplatin, carboplatin, docetaxel, oxaliplatin, paclitaxel, pemetrexed) Ranbaxy (oxaliplatin) Roche (atezolizumab, alectinib) Sandoz (cisplatin, pemetrexed) Seacross Pharmaceuticals (paclitaxel,

Final stakeholder list for the evaluation of nivolumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6310] Issue date: February 2025



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 British Transplantation Society Cancer Research UK Lung Cancer and Mesothelioma Clinical Expert Group Lung Cancer Nursing UK National Heart and Lung Institute NHS Blood and Transplant Primary Care Respiratory Society Royal College of Anaesthetists Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal College of Radiologists Royal College of Surgeons Royal Pharmaceutical Society Royal Society of Medicine Society and College of Radiographers UK Clinical Pharmacy Association UK Oncology Nursing Society Others Department of Health and Social Care NHS England 	oxaliplatin, docetaxel) Teva UK (paclitaxel) Zentiva (pemetrexed) Relevant research groups Cochrane Lung Cancer Group Cochrane UK Genomics England Institute of Cancer Research MRC Clinical Trials Unit National Institute for Health Research Associated Public Health groups Public Health Wales UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.


Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

Final stakeholder list for the evaluation of nivolumab as neoadjuvant (with chemotherapy) and adjuvant (as monotherapy) treatment for resectable non-small-cell lung cancer [ID6310] Issue date: February 2025



The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.